Current Options and Future Perspectives in the Treatment of Dyslipidemia
- PMID:36012957
- PMCID: PMC9410330
- DOI: 10.3390/jcm11164716
Current Options and Future Perspectives in the Treatment of Dyslipidemia
Abstract
Low-density lipoprotein cholesterol (LDL-C) plays a crucial role in the development of atherosclerosis. Statin therapy is the standard treatment for lowering LDL-C in primary and secondary prevention. However, some patients do not reach optimal LDL-C target levels or do not tolerate statins, especially when taking high doses long-term. Combining statins with different therapeutic approaches and testing other new drugs is the future key to reducing the burden of cardiovascular disease (CVD). Recently, several new cholesterol-lowering drugs have been developed and approved; others are promising results, enriching the pharmacological armamentarium beyond statins. Triglycerides also play an important role in the development of CVD; new therapeutic approaches are also very promising for their treatment. Familial hypercholesterolemia (FH) can lead to CVD early in life. These patients respond poorly to conventional therapies. Recently, however, new and promising pharmacological strategies have become available. This narrative review provides an overview of the new drugs for the treatment of dyslipidemia, their current status, ongoing clinical or preclinical trials, and their prospects. We also discuss the new alternative therapies for the treatment of dyslipidemia and their relevance to practice.
Keywords: ANGPTL3 inhibitors; LXR agonists; PCSK9 inhibitors; PPARβ/δ; bempedoic acid; dyslipidemia; inclisiran; lomitapide; mipomersen; volanesorsen.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
- New and emerging lipid-modifying drugs to lower LDL cholesterol.Kosmas CE, Pantou D, Sourlas A, Papakonstantinou EJ, Echavarria Uceta R, Guzman E.Kosmas CE, et al.Drugs Context. 2021 Nov 1;10:2021-8-3. doi: 10.7573/dic.2021-8-3. eCollection 2021.Drugs Context. 2021.PMID:34795777Free PMC article.Review.
- New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.Sahebkar A, Watts GF.Sahebkar A, et al.Clin Ther. 2013 Aug;35(8):1082-98. doi: 10.1016/j.clinthera.2013.06.019. Epub 2013 Aug 8.Clin Ther. 2013.PMID:23932550Review.
- Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.Agabiti Rosei E, Salvetti M.Agabiti Rosei E, et al.High Blood Press Cardiovasc Prev. 2016 Sep;23(3):217-30. doi: 10.1007/s40292-016-0155-2. Epub 2016 Aug 27.High Blood Press Cardiovasc Prev. 2016.PMID:27567901Free PMC article.Review.
- New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B: JACC Focus Seminar 1/4.Nurmohamed NS, Navar AM, Kastelein JJP.Nurmohamed NS, et al.J Am Coll Cardiol. 2021 Mar 30;77(12):1564-1575. doi: 10.1016/j.jacc.2020.11.079.J Am Coll Cardiol. 2021.PMID:33766264Review.
- Beyond Statins and PCSK9 Inhibitors: Updates in Management of Familial and Refractory Hypercholesterolemias.Rached F, Santos RD.Rached F, et al.Curr Cardiol Rep. 2021 Jun 3;23(7):83. doi: 10.1007/s11886-021-01514-2.Curr Cardiol Rep. 2021.PMID:34081216Review.
Cited by
- Recent Pharmacological Options in Type 2 Diabetes and Synergic Mechanism in Cardiovascular Disease.Andreadi A, Muscoli S, Tajmir R, Meloni M, Muscoli C, Ilari S, Mollace V, Della Morte D, Bellia A, Di Daniele N, Tesauro M, Lauro D.Andreadi A, et al.Int J Mol Sci. 2023 Jan 13;24(2):1646. doi: 10.3390/ijms24021646.Int J Mol Sci. 2023.PMID:36675160Free PMC article.Review.
- Inclisiran: a novel drug for the treatment of dyslipidemia.Nadeem A, Tariq R, Basaria A.Nadeem A, et al.Ann Med Surg (Lond). 2023 Jan 12;85(1):59-60. doi: 10.1097/MS9.0000000000000089. eCollection 2023 Jan.Ann Med Surg (Lond). 2023.PMID:36742122Free PMC article.No abstract available.
- Short-Course High-Intensity Statin Treatment during Admission for Myocardial Infarction and LDL-Cholesterol Reduction-Impact on Tailored Lipid-Lowering Therapy at Discharge.Marcos-Garcés V, Merenciano-González H, Martínez Mas ML, Palau P, Climent Alberola JI, Perez N, López-Bueno L, Esteban Argente MC, Valls Reig M, Muñoz Alcover R, Pradillas Contreras I, Arizón Benito A, Payá Rubio A, Ríos-Navarro C, de Dios E, Gavara J, Chorro FJ, Sanchis J, Bodi V.Marcos-Garcés V, et al.J Clin Med. 2023 Dec 25;13(1):127. doi: 10.3390/jcm13010127.J Clin Med. 2023.PMID:38202134Free PMC article.
- Advances in Treatment of Dyslipidemia.Dybiec J, Baran W, Dąbek B, Fularski P, Młynarska E, Radzioch E, Rysz J, Franczyk B.Dybiec J, et al.Int J Mol Sci. 2023 Aug 27;24(17):13288. doi: 10.3390/ijms241713288.Int J Mol Sci. 2023.PMID:37686091Free PMC article.Review.
- Targeting macrophages in atherosclerosis using nanocarriers loaded with liver X receptor agonists: A narrow review.Yang TM, Miao M, Yu WQ, Wang X, Xia FJ, Li YJ, Guo SD.Yang TM, et al.Front Mol Biosci. 2023 Mar 2;10:1147699. doi: 10.3389/fmolb.2023.1147699. eCollection 2023.Front Mol Biosci. 2023.PMID:36936982Free PMC article.Review.
References
- [(accessed on 7 March 2022)]. Available online:https://www.who.int/news/item/09-12-2020-who-reveals-leading-causes-of-d....
- Colin S., Chinetti-Gbaguidi G., Kuivenhoven J.A., Staels B. Emerging Small Molecule Drugs. Handb. Exp. Pharmacol. 2015;224:617–630. - PubMed
- Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., Kirby A., Sourjina T., Peto R., Collins R., et al. Efficacy and Safety of Cholesterol-Lowering Treatment: Prospective Meta-Analysis of Data from 90,056 Participants in 14 Randomised Trials of Statins. Lancet Lond. Engl. 2005;366:1267–1278. - PubMed
Publication types
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous